Switch to:

Antares Pharma EV-to-EBITDA

: 61.15 (As of Today)
View and export this data going back to 1996. Start your Free Trial

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Antares Pharma's enterprise value is $461.9 Mil. Antares Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2020 was $7.6 Mil. Therefore, Antares Pharma's EV-to-EBITDA for today is 61.15.

NAS:ATRS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1678   Med: -18.8   Max: 270.3
Current: 61.14

-1678
270.3

During the past 13 years, the highest EV-to-EBITDA of Antares Pharma was 270.30. The lowest was -1678.00. And the median was -18.80.

NAS:ATRS's EV-to-EBITDA is ranked lower than
87% of the 367 Companies
in the Medical Devices & Instruments industry.

( Industry Median: 19.03 vs. NAS:ATRS: 61.14 )

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2020-05-27), Antares Pharma's stock price is $2.81. Antares Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2020 was $0.02. Therefore, Antares Pharma's PE Ratio for today is 140.50.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Antares Pharma EV-to-EBITDA Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Antares Pharma Annual Data
Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.37 -14.89 -23.03 -386.81 189.27

Antares Pharma Quarterly Data
Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20
EV-to-EBITDA Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,386.41 262.86 101.37 189.27 51.25

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Antares Pharma EV-to-EBITDA Distribution

* The bar in red indicates where Antares Pharma's EV-to-EBITDA falls into.



Antares Pharma EV-to-EBITDA Calculation

Antares Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=461.944/7.554
=61.15

Antares Pharma's current Enterprise Value is $461.9 Mil.
Antares Pharma's EBITDA for the trailing twelve months (TTM) ended in Mar. 2020 was -0.854 (Jun. 2019 ) + 2.718 (Sep. 2019 ) + 6.415 (Dec. 2019 ) + -0.725 (Mar. 2020 ) = $7.6 Mil.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Antares Pharma  (NAS:ATRS) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Antares Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=2.81/0.02
=140.50

Antares Pharma's share price for today is $2.81.
Antares Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2020 was -0.01 (Jun. 2019 ) + 0.01 (Sep. 2019 ) + 0.03 (Dec. 2019 ) + -0.01 (Mar. 2020 ) = $0.02.

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Antares Pharma EV-to-EBITDA Related Terms


Antares Pharma EV-to-EBITDA Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)